TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05661201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEROFE
Description: weekly doses of NEROFE (48-288 mg/m2) (dose level 1: 96 mg/m2, dose level -1: 48 mg/m2, dose level 2: 192 mg/m2, dose level 3: 288 mg/m2), intravenously over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEROFE
Description: weekly doses of NEROFE (48-288 mg/m2) (dose level 1: 96 mg/m2, dose level -1: 48 mg/m2, dose level 2: 192 mg/m2, dose level 3: 288 mg/m2), intravenously over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEROFE
Description: weekly doses of NEROFE (48-288 mg/m2) (dose level 1: 96 mg/m2, dose level -1: 48 mg/m2, dose level 2: 192 mg/m2, dose level 3: 288 mg/m2), intravenously over 60 minutes
Study: NCT05173792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK119
Description: Subjects will receive AK119 intravenously.
Study: NCT05988840

Intervention type: OTHER
Intervention: Acquisition and analysis of relationships between Longitudinal Emotional Signals produced by a software and Self-questionnaires.
Description: Using the tool developed by Emobot, EMOACQ-1 is a study that passively and non-interventionaly collects data by capturing patients' facial expressions throughout the day, and then measures the correlation between emotional signals and the results of measurement questionnaires used in psychiatry.

Intervention type: OTHER
Intervention: Acquisition and analysis of relationships between Longitudinal Emotional Signals produced by a software and Self-questionnaires.
Description: Using the tool developed by Emobot, EMOACQ-1 is a study that passively and non-interventionaly collects data by capturing patients' facial expressions throughout the day, and then measures the correlation between emotional signals and the results of measurement questionnaires used in psychiatry.
Study: NCT06507176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: flexible ureteroscopic lithotripsy
Description: This group of patients underwent flexible ureteroscopic lithotripsy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous nephrolithotomy
Description: This group of patients underwent percutaneous nephrolithotomy.
Study: NCT05661201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEROFE
Description: weekly doses of NEROFE (48-288 mg/m2) (dose level 1: 96 mg/m2, dose level -1: 48 mg/m2, dose level 2: 192 mg/m2, dose level 3: 288 mg/m2), intravenously over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;
Study: NCT05543434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: anti-inflammatory, anti-edematous, osseoinductive.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: anti-inflammatory, anti-edematous, osseoinductive.
Study: NCT06291961

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CS-101 injection
Description: Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
Study: NCT06426576

Intervention type: OTHER
Group type: OTHER
Intervention: Standard one-off instruction using a scale
Description: The permitted weight is demonstrated to the patient once using a scale in the static position. The patient repeatedly places the foot with the permitted weight on a scale in order to develop a feeling for the load. After this exercise in the static position, the patient applies the perceived load to dynamic activities of daily living without receiving any feedback.~The instruction is given by a trained physiotherapist. Simultaneously with the instruction, the effective weight applied on the leg will be measured using instrumented insoles without any feedback.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plantar pressure insoles
Description: The insoles are used in both static and dynamic conditions such as walking straight along the hallway or walking stairs if applicable. Initial instruction is given by a trained physiotherapist and will be continuously applied at home using the smartphone app for 5 out of 7 days per week during the first 2 weeks after surgery.
Study: NCT06190665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB-TACE with visualable microspheres
Description: Drug-eluting Beads Transcatheter Arterial Chemoembolization(DEB-TACE) with visualable microspheres

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DEB-TACE with PVA microspheres
Description: Drug-eluting Beads Transcatheter Arterial Chemoembolization(DEB-TACE) with polyvinyl alcohol microspheres
Study: NCT04887038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT-015
Description: Each study part (A,B and C) will be completed sequentially, but with partial overlapping. The first cohort of Part B (Cohort B1) may be initiated after safety, tolerability and available PK data are assessed and deemed suitable to continue for a single dose on Part A that is equal to or greater than the total exposure of cohort B1. Part C (Cohort C1 \& C2) may be initiated after safety, tolerability and PK data are assessed and deemed suitable to continue for a single dose in part A that is at least double the specified dose from part C.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for SRT-015
Description: Matching Placebo
Study: NCT06493383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B plano cosmetic contact lenses
Description: Commercially approved colored contact lenses worn for cosmetic purposes to alter or enhance the apparent color of the eye
Study: NCT06236581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GEM Intervention
Description: Lifestyle coaching
Study: NCT06009497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim 10 µg/kg, subcutaneous injection, once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Ciclosporin 3-5mg/kg/d, adjust the dose to keep trough ciclosporin plasma concentration 100-200ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Ciclosporin 3-5mg/kg/d, adjust the dose to keep trough ciclosporin plasma concentration 100-200ng/ml.
Study: NCT05020119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-expanded cell therapy.
Description: Infusion of personalized neoantigen-expanded T (CIK) cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-expanded cell therapy.
Description: Infusion of personalized neoantigen-expanded T (CIK) cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-expanded cell therapy.
Description: Infusion of personalized neoantigen-expanded T (CIK) cells
Study: NCT05753969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MT1 Device
Description: Pre-and post-evaluation in MT1 device following stimulant treatment or placebo control

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MT1 Device
Description: Pre-and post-evaluation in MT1 device following stimulant treatment or placebo control
Study: NCT05508165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stream Dx
Description: home uroflowmetry device

Intervention type: DEVICE
Group type: OTHER
Intervention: Stream Dx
Description: home uroflowmetry device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DFree
Description: at home wearable bladder scanner

Intervention type: DEVICE
Group type: OTHER
Intervention: DFree
Description: at home wearable bladder scanner

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TestCard
Description: mobile urinalysis reader

Intervention type: DEVICE
Group type: OTHER
Intervention: TestCard
Description: mobile urinalysis reader
Study: NCT05816473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LLM
Description: Use of a Large Language Model (LLM) chatbot interface to Interact with the Machine Learning Algorithm and interpretability dashboard.
Study: NCT05529173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 10%
Description: Nasal swab stick application of Povidone-Iodine 10% prior to surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl Solution
Description: Nasal swab stick application of 0.9% NaCl Solution prior to surgery
Study: NCT04865978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Patients randomized to apixaban will be started on a dose of 5 mg BID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Patients randomized to warfarin will be started on a dose per institutional protocol and titrated to an INR goal of 2.0 - 2.5.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LVAD implant
Description: Subjects will undergo HeartMate 3 LVAD implant prior to randomization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LVAD implant
Description: Subjects will undergo HeartMate 3 LVAD implant prior to randomization
Study: NCT06101862

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CCTA
Description: Participants will be examined with CCTA during admission.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional ICA
Description: Patients will be examined with conventional standard-of-care ICA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Team-based interventional triage
Description: The CCTA will be discussed at a coronary CT-team conference to establish the treatment strategy and provide guidance for any necessary interventional procedure.
Study: NCT06232421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foscelantan
Description: Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1 produced by UNITEHPROM BSU, Republic of Belarus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foscelantan
Description: Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1 produced by UNITEHPROM BSU, Republic of Belarus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidon-iodine
Description: Povidone-iodine solution 100 mg/ml produced by BelAseptika CJSC, Republic of Belarus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidon-iodine
Description: Povidone-iodine solution 100 mg/ml produced by BelAseptika CJSC, Republic of Belarus
Study: NCT06225531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autobiographical Memory Based Intervention
Description: The intervention involves 6 sessions of therapeutic input based around autobiographical memories. Memory based activities will broadly follow the 5 stages outlines in the broad-minded affective coping (BMAC) procedure, but with a focus on specific memories. It will follow the following structure:~Session 1 - Introduction and Familiarisation Session 2 - Neutral Memories Session 3 - Positive Memories Session 4 - Memories of Moves Away from Suicidality Session 5 - Practice of Preferred Memory (from Sessions 2-4) Session 6 - Continued Practice and Post-Intervention Planning
Study: NCT05877287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness-based stress reduction program
Description: The FTSA program will be carried out once a week for 60 minutes, for 8 weeks, in a total of 8 sessions. The program will be conducted in face-to-face groups. Sessions will be held in a suitable area in the practice area. In each 60-minute session, it is planned to be 20 minutes of narration on the subject of the session, accompanied by a power point presentation, and the remaining 40 minutes of exercise, meditation practices and sharing experiences.
Study: NCT06478771

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Essix retainer
Description: A clear plastic removable retainer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Essix retainer
Description: A clear plastic removable retainer.
Study: NCT05712889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIP236 (Q3W)
Description: VIP236 will be administered by IV infusion once every 3 weeks, for a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIP236 (Q2W)
Description: VIP236 will be administered by IV infusion once every 2 weeks, for a 28-day cycle.
Study: NCT06431646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A web-based education intervention developed for university students with PMS
Description: The web-based education program includes the definition, prevalence, importance, causes, symptoms, diagnosis, risk factors, management strategies and treatment options of PMS. The education emphasizes non-pharmacological strategies for managing PMS, including diet, exercise and body mass index (BMI), sleep hygiene, smoking cessation, stress management, as well as vitamin and mineral supplements, herbal therapy, acupuncture, acupressure and reflexology.
Study: NCT06077071

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ViewRay MRIdian Stereotactic Radiosurgery
Description: Participants will undergo stereotactic radiosurgery of the spinal cord on the ViewRay MRIdian, a hybrid MRI-linac platform, with 40 Gy in 5 fractions prescribed to the planning target volume (PTV).
Study: NCT06077747

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coil Embolization of the Lumbar Vein
Description: Catheter based venography will first confirm Nutcracker physiology with retrograde lumbar vein flow and epidural venous plexus congestion. The lumbar vein will then be coil embolized.
Study: NCT06478771

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lingual retainer
Description: A fixed retainer placed on the lingual side of the teeth.
Study: NCT04181463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isopropyl Alcohol
Description: Given via nasal inhalation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given via nasal inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06478771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lingual retainer
Description: A fixed retainer placed on the lingual side of the teeth.
Study: NCT05599581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tu'Washindi
Description: Tu'Washindi consists of 3 primary components:~1. PrEP Adherence Support Clubs: Eight 2-hour sessions that occur over the intervention period: twice per month for the first 2 months \& once per month for the remaining 4 months. Sessions will use structured \& unstructured activities designed to improve outcomes expectations, increase self-efficacy to use PrEP safely \& consistently, increase peer support for PrEP use, provide access to community IPV resources \& provide skills for healthy communication \& PrEP disclosure with male partners.~2. Community Male Sensitization conducted weekly over the first 3 months of the intervention period aimed to increase PrEP knowledge, reduce stigma, \& promote healthy relationship communication.~3. Buddy Days, which take place 3 months into the intervention period, designed to bring participants \& their male partners together to learn about PrEP, discuss community attitudes \& concerns regarding PrEP use, \& promote HIV prevention \& family well-being.
Study: NCT05919667

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy and plant-based dairy beverages and solids
Description: Crossover design: participants received all treatment arms in a randomized order

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy and plant-based dairy beverages and solids
Description: Crossover design: participants received all treatment arms in a randomized order

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy and plant-based dairy beverages and solids
Description: Crossover design: participants received all treatment arms in a randomized order

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy and plant-based dairy beverages and solids
Description: Crossover design: participants received all treatment arms in a randomized order

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy and plant-based dairy beverages and solids
Description: Crossover design: participants received all treatment arms in a randomized order
Study: NCT05311046

Intervention type: DIAGNOSTIC_TEST
Intervention: Pediatric sepsis screening tool (either algorithmic or manual)
Description: All participating institutions employ either an algorithmic, manual, or combined algorithmic/manual pediatric sepsis screening protocol for patients that present with fever and/or a concern for infection. While the specific parameters tested in screening tools differ, they generally consist of tests for a systemic inflammatory response (e.g. SIRS) and/or organ dysfunction (e.g. SOFA) and/or high susceptibility (e.g. immunocompromised) factors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pediatric sepsis screening tool (either algorithmic or manual)
Description: All participating institutions employ either an algorithmic, manual, or combined algorithmic/manual pediatric sepsis screening protocol for patients that present with fever and/or a concern for infection. While the specific parameters tested in screening tools differ, they generally consist of tests for a systemic inflammatory response (e.g. SIRS) and/or organ dysfunction (e.g. SOFA) and/or high susceptibility (e.g. immunocompromised) factors.
Study: NCT05309135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCEC-1
Description: HCEC-1 = human cultured corneal endothelial cells and Rho kinase Y-27632 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCEC-1
Description: HCEC-1 = human cultured corneal endothelial cells and Rho kinase Y-27632 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCEC-1
Description: HCEC-1 = human cultured corneal endothelial cells and Rho kinase Y-27632 inhibitor
Study: NCT04823091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine + Cyclophosphamide + CAR7-T Cells
Description: fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 250 mg/kg on day -5, -4, and -3; CAR7-T Cells on day 0.
Study: NCT05921981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisensorial Stimulation
Description: Multisensory stimulation in newborns involves the deliberate and simultaneous activation of multiple sensory modalities to provide sensory experiences that promote development and enhance learning. Newborns are naturally inclined to explore and make sense of their environment through their senses, including touch, sight, sound, taste, and smell.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: White Noise
Description: White Noise
Study: NCT06438640

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Anesthesia Choice-HF Model
Description: Brief clinician training on shared decision making, paired with provision of a 1-page tabular format conversation aid listing answers to frequently asked questions regarding common anesthesia options for hip fracture surgery (spinal anesthesia; general anesthesia)
Study: NCT06273579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group - Verbal expert instructor feedback in AI's words
Description: Expert instructor assigned to tutor this group will receive error detection data from the ICEMS. They will also be provided with a list of commands that the ICEMS uses. When the system detects an error in a student's performance for a given metric, the expert instructor must deliver this command in the same words as the ICEMS.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group - Verbal expert instructor feedback in expert's own words
Description: Expert instructor assigned to tutor this group will receive error detection data from the ICEMS. When the system detects an error in a student's performance for a given metric, the expert will deliver feedback in their own words.
Study: NCT06331910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin eye drops
Description: Insulin eye drops deliver insulin directly to the cornea, They exploit insulin's ability to stimulate cell growth, potentially reducing healing time with minimal side effects.
Study: NCT04403347

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Innovative Dietary Formulation (Patent ID: CN110250417A)
Description: In addition to regular diets and usual care of hypertension, additional innovative natural dietary formulation derived from tartary buckwheat will be orally taken 3 times per day.
Study: NCT03064282

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: observation of skin changes if any

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: papaverine
Description: observation of symptoms
Study: NCT04403347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 50mg per day
Description: In addition to regular diets and usual care of hypertension, antihypertensive medication will be orally taken (Losartan 50mg per day).
Study: NCT05372744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Placebo labelled as antidepressant
Description: Participants receive an active nasal spray that is in fact a placebo with a specific framing in regards to its affect-regulatory characteristics, respectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Placebo labelled as antidepressant
Description: Participants receive an active nasal spray that is in fact a placebo with a specific framing in regards to its affect-regulatory characteristics, respectively.
Study: NCT05569512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Administered by intravenous infusion
Study: NCT06049407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participation in a socio-emotional competence program through a technological platform (EMOWELL)
Description: (1) Participants who meet the inclusion criteria will be contacted. (2) Participants will answer the questionnaire battery (T1) (3) Participants will participate in the intervention by remotely playing the EMOWELL desktop serious game and the EMOWELL app. (4) They will answer the T2 questionnaires. (5) They will answer the follow-up (T3) questionnaires.